Literature DB >> 16442314

Antiepileptic drugs and liver disease.

Syed Nizamuddin Ahmed1, Zaeem A Siddiqi.   

Abstract

Antiepileptic drugs (AEDs) are no longer restricted to the treatment of epilepsy. These are widely used in a broad spectrum of psychiatric and neurological disorders. Liver plays a major role in the metabolism of a majority of these drugs. Hepatotoxicity is rare, but a real concern when initiating therapy. Likewise, liver disease can adversely affect the biotransformation of some of these drugs. This manuscript addresses the significance of elevated liver enzymes associated with AED use, the role of therapeutic drug monitoring, pharmacokinetics during liver disease and potential risk of hepatotoxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16442314     DOI: 10.1016/j.seizure.2005.12.009

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  20 in total

1.  The effect of hyperglycinemic treatment in captive-bred Vervet monkeys (Chlorocebus aethiops).

Authors:  Zandisiwe E Magwebu; Mikateko Mazinu; Sahar Abdul-Rasool; Chesa G Chauke
Journal:  Metab Brain Dis       Date:  2019-06-22       Impact factor: 3.584

2.  Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study.

Authors:  Jean P Molleston; Robert J Fontana; M James Lopez; David E Kleiner; Jiezhun Gu; Naga Chalasani
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-08       Impact factor: 2.839

3.  Clinical Pharmacokinetic Monitoring of Free Valproic Acid Levels: A Systematic Review.

Authors:  Kevin Lin; Vivien F S Cao; Charles Au; Karen Dahri
Journal:  Clin Pharmacokinet       Date:  2022-08-30       Impact factor: 5.577

Review 4.  Dispensability of Annual Laboratory Follow-Up After More than 2 Years of Valproic Acid Use: A Systematic Review.

Authors:  Rosanne W Meijboom; Koen P Grootens
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

5.  Use and safety profile of antiepileptic drugs in Italy.

Authors:  M L Iorio; U Moretti; S Colcera; L Magro; I Meneghelli; D Motola; A L Rivolta; F Salvo; G P Velo
Journal:  Eur J Clin Pharmacol       Date:  2007-02-16       Impact factor: 2.953

6.  Lacosamide as add-on treatment of focal symptomatic epilepsy in a patient with alcoholic liver cirrhosis.

Authors:  A Romigi; F Placidi; C Liguori; F Izzi; A Marchi; E Tarquini; M Albanese; N B Mercuri
Journal:  Epilepsy Behav Case Rep       Date:  2014-09-24

Review 7.  Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development.

Authors:  Abdul Wahab
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-05

Review 8.  Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C.

Authors:  Alexis Thibault; Suzanne Brissette; Didier Jutras-Aswad
Journal:  Addict Sci Clin Pract       Date:  2015-02-24

Review 9.  Management of chronic pain in elderly, frail patients: finding a suitable, personalized method of control.

Authors:  Rahul Rastogi; Brian D Meek
Journal:  Clin Interv Aging       Date:  2013-01-16       Impact factor: 4.458

10.  Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia.

Authors:  Cecilia Maldonado; Natalia Guevara; Cecilia Queijo; Raquel González; Pietro Fagiolino; Marta Vázquez
Journal:  Biomed Res Int       Date:  2016-02-21       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.